EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Acrux Limited (ARUXF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Acrux Limited $0.01, price $0.02, upside -40.8%, quality 20 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Australia

AL Acrux Limited logo Thin data Jun 24, 2026

Acrux Limited

ARUXF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0100 · Strongly overvalued (−40.8%)
!Quality 20/100
!Weak Growth (revenue 5y −1.0 %/yr)
!Loss-making · -83.8% net margin (TTM)
!Low debt · negative free cash flow
!Mixed vs. peers (4/10)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Acrux Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.5633 $0.0169 Fair Value $0.0100 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 24, 2026.

How to read this chart

60‑month range $0.0169 – $0.5633 · the $0.0169 price screens above the $0.0100 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jun 24, 2026.

Follow Acrux in your weekly email

Every Wednesday you see whether Acrux is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally.

Show more

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazole, a topical solution used to treat fungal infections of toenails; Nitroglycerin 0.4%, an ointment for the treatment of pain associated with chronic anal fissure; and Acyclovir 5%, a cream for the treatment of cold sores. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Stock analysis

Acrux Limited (ARUXF) currently trades at $0.0169, while our model-based Fair Value estimate is $0.0100, 40.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Acrux Limited reported revenue of A$1.2M in FY2025 versus A$1.3M in FY2021, a compound −2.9%/yr. Reported net income was −A$5.9M in FY2025.

Key figures

Market cap $8.8M · P/S ratio 3.14 · Net margin −83.8% · Return on equity −102% · Return on assets (EBIT) −97.8% · Operating margin −102% · Revenue (TTM) $2.8M · Revenue growth (YoY) +13.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 66% below its 52-week high and 412% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −41%, ARUXF screens richer than that median.

Notify me when ARUXF reaches fair value

Put ARUXF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 20/100

Of which business quality 20 · Market factors (momentum, volatility) 17

Profitability 6
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 9
Earnings quality: real cash, not paper profit
Fin. Strength 16
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 31
Calm price path (market factor)
Momentum 18
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 2
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−76.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.0%
Start year 2020 (pandemic). Over 10 years: −26.1% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−963.8% (2020) → −753.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ARUXF screens overvalued: fair value 41% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Acrux Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 20 · Bottom 25%
Fair Value upside +200.0% · Top 25%
Profitability
Return on assets −57.2% · Bottom 25%
Net margin (TTM) −83.8% · Bottom 25%
Operating margin (TTM) −102.3% · Bottom 25%
Growth and dividend
Revenue growth 13.5% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.63× · Priciest 25%
P/S (TTM) 3.14× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)68 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $527.67 $580.44 +10%
Regeneron Pharmaceuticals, Inc REGN $752.25 $1,275 +69%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$175.35 A$192.89 +10%
Samsung Biologics Co 207940 1,354,000 KRW 1,489,400 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Acrux Limited · Fair Value
$0.0100 −41%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Acrux Limited Fair Value". https://www.fairvalue-calculator.com/stock/ARUXF

Frequently asked questions

Is Acrux Limited (ARUXF) overvalued or undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.0100 versus the last price from Sep 25, 2026 of $0.0169, about −41% upside (overvalued).
What is the fair value of ARUXF?
Our model-based fair value for Acrux Limited is $0.0100 (as of Jun 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $0.0169.
What is the quality score of ARUXF?
Acrux Limited has a Quality Score of 20/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Acrux Limited (ARUXF)?
Our model-based price target is the fair value of $0.0100 (as of Jun 24, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Acrux Limited stock forecast for 2026?
Our models put fair value at $0.0100, about −41% upside versus the last price from Sep 25, 2026 of $0.0169 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Acrux Limited (ARUXF)?
Acrux Limited reported trailing-twelve-month revenue of about $2.8M (latest available figure, as of Jun 24, 2026).
What is the intrinsic value of Acrux Limited (ARUXF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Acrux Limited it is $0.0100 per share (as of Jun 24, 2026), against a price of $0.0169. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Acrux Limited stock overvalued or undervalued in 2026?
As of Jun 24, 2026, ARUXF trades above its calculated fair value: price $0.0169, fair value $0.0100, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ARUXF?
No. The price is what the market pays today ($0.0169); the fair value is what the company's own numbers justify ($0.0100). For Acrux Limited the two are $0.0069 per share apart. That gap is exactly why we show both numbers side by side.
How much is Acrux Limited worth?
The market values Acrux Limited at about $8.8M (market capitalisation, as of Jun 24, 2026). Per share that is $0.0169; our models calculate a fair value of $0.0100 per share.
How solid is the balance sheet of Acrux Limited (ARUXF)?
Balance-sheet figures for Acrux Limited (as of Jun 24, 2026): return on equity −102.2%. They feed the Quality Score of 20/100, which measures business quality independently of the share price.
How far is ARUXF from its 52-week high?
Acrux Limited trades at $0.0169, about 66% below its 52-week high of $0.0500 and 412% above the low of $0.0033 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0100 is for.
Which stocks are comparable to Acrux Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Acrux Limited stock attractive at the current price?
The data as of Jun 24, 2026: price $0.0169, calculated fair value $0.0100 (−41%), Quality Score 20/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ARUXF calculated?
We run Acrux Limited through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Acrux Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Acrux Limited (ARUXF)?
The latest price we hold is from Sep 25, 2026 and stands at $0.0169. Our model-based fair value is $0.0100, about −41% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Acrux Limited right now?
Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Acrux Limited

How large is the market capitalisation of Acrux Limited (ARUXF)?
The market capitalisation of Acrux Limited is $8.8M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Acrux Limited (ARUXF)?
The price-to-sales ratio of Acrux Limited is 3.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Acrux Limited (ARUXF)?
The net margin of Acrux Limited is −83.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Acrux Limited (ARUXF)?
The return on equity (ROE) of Acrux Limited is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Acrux Limited (ARUXF)?
On an EBIT basis the return on assets of Acrux Limited is −97.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Acrux Limited (ARUXF)?
The operating margin of Acrux Limited is −102% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Acrux Limited (ARUXF)?
Revenue at Acrux Limited is growing +13.5% versus a year earlier (3y avg −11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Acrux Limited (ARUXF) generate?
The free cash flow of Acrux Limited is −$5.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Acrux Limited (ARUXF) carry?
The net debt of Acrux Limited is $2.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Acrux Limited in the live analysis

One click puts Acrux Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.